GLP-1 analogue therapy for obesity in people from Asia

Lancet Diabetes Endocrinol. 2024 Mar;12(3):153-154. doi: 10.1016/S2213-8587(24)00031-7. Epub 2024 Feb 5.

Authors

Bernard Khoo¹, Tricia M-M Tan²

Affiliations

¹ Endocrinology, Division of Medicine, University College London, Royal Free Campus, London NW3 2PF, UK.
² Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0HS, UK. Electronic address: t.tan@imperial.ac.uk.

PMID: 38330985
DOI: 10.1016/S2213-8587(24)00031-7

No abstract available

MeSH terms

Asia / epidemiology
Diabetes Mellitus, Type 2*
Glucagon-Like Peptide 1 / therapeutic use
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents
Obesity / drug therapy

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents